DrugDashboards

Ondansetron

Ondansetron · ONDANSETRON HYDROCHLORIDE 2 mg/mL · Injection · Intramuscular; Intravenous · West-Ward Pharmaceuticals Corp

NDC 00143-9890-10 · 10 VIAL, MULTI-DOSE in 1 CARTON / 20 mL in 1 VIAL, MULTI-DOSE · ANDA · View full market →

The short version

16 companies supply this market — deep enough that no single failure threatens the supply. The price has jumped 180% in a year, to $0.3226 per unit — sharp rises like this often mean supply is already tightening. Historically, drugs in this position went on to a new shortage within 90 days about 0.3% of the time — roughly 2× the typical drug (0.1%).

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

Medicare Part D

No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.

How Part D pricing works →

NADAC price per unit

$0$0.2$0.4Nov 2016Sep 2020$0.3226
2 price points · per · last surveyed Invalid DateSource: CMS NADAC

Medicaid spend (2025)

$16
28 prescriptions paid by Medicaid nationally · all Medicaid spend →

Supply fragility

Not scored — fragility is computed for NADAC-priced NDCs.

90-day shortage risk (model v2)

0.3%chance of a new FDA shortage posting for ondansetron (injectable) in the next 90 days

sterile injectable · sole-source market

For scale: the typical drug’s chance is about 0.1% — this one is 2× that.

Backtested statistical model over the whole market, not this package alone. Model details →

Where it's made

Establishments this product's FDA label declares, located via FDA registration data. How we built this →

Is this a "specialty" drug?

There's no legal definition — it meets 1 of 6 public criteria. Why that matters →

  • Part D specialty tier
  • Costs ≥ $950/fill · avg $14.79 per prescription
  • Biologic (BLA)
  • Injectable / infused
  • Orphan-drug exclusivity
  • REMS program

Regulatory

Application
ANDA076781
TE code
—
Approval date
Dec 26, 2006
Patents / exclusivity
None on file

Shortage history

No FDA shortage reports for this drug or its presentations.

Recalls (this NDC)

No enforcement reports list this package NDC.

Manufacturers of Ondansetron (Injection)

LabelerStrengthFirst seenLast seen
Fosun Pharma USA Inc.ONDANSETRON HYDROCHLORIDE 2 mg/mLJul 15, 2026Sep 3, 2026
Gland Pharma LimitedONDANSETRON HYDROCHLORIDE 2 mg/mLJul 15, 2026Sep 3, 2026
HF Acquisition Co LLC, DBA HealthFirstONDANSETRON HYDROCHLORIDE 2 mg/mLJul 15, 2026Sep 3, 2026
Medical Purchasing Solutions, LLCONDANSETRON HYDROCHLORIDE 2 mg/mLJul 15, 2026Sep 3, 2026
West-Ward Pharmaceuticals CorpONDANSETRON HYDROCHLORIDE 2 mg/mLJul 15, 2026Sep 3, 2026
A-S Medication SolutionsONDANSETRON HYDROCHLORIDE 2 mg/mLJul 15, 2026Sep 2, 2026
Accord Healthcare, Inc.ONDANSETRON 2 mg/mLJul 15, 2026Sep 2, 2026
Apotex Corp.ONDANSETRON HYDROCHLORIDE 2 mg/mLJul 15, 2026Sep 2, 2026
Civica, Inc.ONDANSETRON HYDROCHLORIDE 2 mg/mLJul 15, 2026Sep 2, 2026
Henry Schein, Inc.ONDANSETRON HYDROCHLORIDE 2 mg/mLJul 15, 2026Sep 2, 2026
Jvet Pharmaceuticals LlcONDANSETRON HYDROCHLORIDE 2 mg/mLJul 15, 2026Sep 2, 2026
ProPharma DistributionONDANSETRON HYDROCHLORIDE 2 mg/mLJul 15, 2026Sep 2, 2026
Sportpharm LLCONDANSETRON HYDROCHLORIDE 2 mg/mLJul 15, 2026Sep 2, 2026
Cardinal Health 107, LLCONDANSETRON HYDROCHLORIDE 2 mg/mLJul 15, 2026Aug 31, 2026
Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.ONDANSETRON HYDROCHLORIDE 2 mg/mLJul 15, 2026Aug 31, 2026
Hikma Pharmaceuticals USA Inc.ONDANSETRON HYDROCHLORIDE 2 mg/mLJul 15, 2026Aug 29, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Ondansetron — NDC 00143-9890-10," retrieved September 3, 2026, https://drugdashboards.com/drug/00143989010.

Free to cite with attribution — see how the data is put together.